chrisvoncsefalvay/vaers-outcomes huggingface dataset:
dizziness, nausea, sweating within minutes of vaccine administration - patient remained seated, visibly sweating, drank some water, started feeling better within 5 minutes. Remained in store 15-20 minutes and was feeling back to normal when left with family. Would contact Dr. if returned or continued.
brain fog Narrative: He reports having developed a feeling of dissociation, which has typically been described as "brain fog" that started about a day after the initial vaccination and persisted for 2x days prior to resolving on its own. No therapies were tried or applied and he does not remember if he had other common adverse effects (AEs) to the vaccine. Normalization of adverse effect reviewed and general recommendations provided if this were to return. RN provided education on common AEs and when to seek care.
COVID; COVID; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): US-ABBVIE-22K-163-4483525-00. A 68-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown), all intramuscular for covid-19 immunisation. The patient's relevant medical history included: "Blood pressure study/not in control", start date: 2020 (ongoing); "Moderate to Severe Chronic Plaque Psoriasis" (unspecified if ongoing). Concomitant medication(s) included: HUMIRA subcutaneous taken for psoriasis. The following information was reported: DRUG INEFFECTIVE (medically significant) with onset 01Jul2022, outcome "unknown", COVID-19 (medically significant) with onset 01Jul2022, outcome "recovered" and all described as "COVID". The patient underwent the following laboratory tests and procedures: Blood glucose: (2022) Unknown Results; SARS-CoV-2 test: (01Jul2022) Positive.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
t all started on day 11 after vaccine that I had generalized pruritus more consistently on scalp, hand/fingers, dorsal foot and pubic area. On day 12 post booster, I developed urticaria in face, forearms, legs, buttocks and inner thighs and chest, treated at home with antihistaminics (Benadryl, Zyrtec) and 10mg of prednisone. Of note, dermographic urticaria noted that worsen on areas of pressure. On day 13, hives were worsening and started experiencing difficulty swallowing and chest wall pain. I went to ER for evaluation. The workup r/o heart etiology or myocarditis (EKG and troponins were negative) and I was discharged with prednisone 50mg for 7 days. I'm currently on day 2 of prednisone.
prior to receiving the vaccine the child could talk,and after administration the child "could no longer talk"; Initial information received on 03-May-2019 regarding an unsolicited valid non-serious case received from a consumer/non-hcp.  This case involves a male patient (age not reported) for whom it was reported that prior to receiving the vaccine the child could talk,and after administration the child "could no longer talk", while he received vaccine  DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On an unknown date, the patient received a a dose of suspect  DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE.(lot number not reported) via unknown route in unknown administration site.  On an unknown date, the patient developed a non-serious prior to receiving the vaccine the child could talk, and after administration the child "could no longer talk" (aphasia) (Unknown latency) following the administration of  DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE.  No relevant tests were reported.  Final diagnosis was prior to receiving the vaccine the child could talk,and after administration the child "could no longer talk".    It was not reported if the patient received a corrective treatment.  The patient outcome is reported as Unknown for prior to receiving the vaccine the child could talk,and after administration the child "could no longer talk" on an unknown date.  There will be no information available on the batch number for this case (reporter refused to provide).  Documents held by the sender: none.
No adverse event; Patient of 6 months-5 years of age received a Moderna COVID-19, bivalent vaccine from the Pink cap vial(10 mcg) instead of blue cap vial(25 mcg), when blue cap was indicated; This spontaneous case was reported by a nurse and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient of 6 months-5 years of age received a Moderna COVID-19, bivalent vaccine from the Pink cap vial(10 mcg) instead of blue cap vial(25 mcg), when blue cap was indicated) and NO ADVERSE EVENT (No adverse event) in a 12-month-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 214K22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 25-Apr-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 10 microgram. On 25-Apr-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced WRONG PRODUCT ADMINISTERED (Patient of 6 months-5 years of age received a Moderna COVID-19, bivalent vaccine from the Pink cap vial(10 mcg) instead of blue cap vial(25 mcg), when blue cap was indicated). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient of 6 months-5 years of age received a Moderna COVID-19, bivalent vaccine from the Pink cap vial(10 mcg) instead of blue cap vial(25 mcg), when blue cap was indicated) and NO ADVERSE EVENT (No adverse event) outcome was unknown. Not Provided      For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patient of 6 months-5 years of age received a Moderna COVID-19, bivalent vaccine from the Pink cap vial(10 mcg) instead of blue cap vial(25 mcg), when blue cap was indicated).    The route of administration of suspect Moderna bivalent was reported as BI. Concomitant medications were not reported.  No treatment information was provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-730780 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-730780:Master case,
As per pt. notice when flu shot was given on 09/14/12 pt. arm got swollen an hour after flu shot given. Pt. complaining pain on her arm. Also, pt. start getting cough and cold. No fever.
Shingles- itching burning rash on back, fever, headache, occurred about 14 days after vaccination, receiving treatment now
A report was received from a consumer on 12/9/03 concerning a 13 year old male vaccinee who inadvertently received 2 doses of Fluvirin on 12/9/03. On 12/9/03, the vaccinee inadvertently received 2 doses of Fluvirin vaccine. The vaccinee complained of tenderness at the site of injection. Follow up pending.
This spontaneous report was received from a 59 years old female patient with aspirin allergy. The patient's medical history included shingles last year. One month ago in November 2012, the patient was vaccinated with ZOSTAVAX (dose, route and lot not reported). No other co-suspects were reported. No concomitant medications were reported. The patient explained that since having ZOSTAVAX about 3 months ago in September 2012, she had developed a rash all over her body. She explained that the rash comes and goes and that she was fine before having this vaccine and at the time of the phone call it was getting worse. The patient was treated with prednisone (manufacturer unknown), topical creams, ALLEGRA, and BENADRYL had been unsuccessful at treating this event. The relatedness for the event was unknown for ZOSTAVAX. It was schedule a blood work. Additional information is not expected.
booster; Left arm really hurts; heart rate is 116 currently; cough; short of breath; Keeps clearing throat; This is a spontaneous report from a contactable consumer (patient). A 63-year-old female patient received bnt162b2 (COMIRNATY- formulation: solution for injection, Batch/Lot Number: FH8020), dose 3 via an unspecified route of administration, administered in Arm Left on 09Nov20211, (at the age of 63-year-old) as DOSE 3 (BOOSTER), SINGLE for covid-19 immunisation. The patient medical history and concomitant medications reported as none. The patient's historical vaccine included first dose of bnt162b2 (COMIRNATY- formulation: solution for injection, Batch/Lot Number: EN6206), dose 1 via an unspecified route of administration, on 05Mar2021, as DOSE 1, SINGLE for covid-19 immunisation and second dose of bnt162b2 (COMIRNATY- formulation: solution for injection, Batch/Lot Number: EN6204), dose 2 via an unspecified route of administration, on 26Mar2021, as DOSE 2, SINGLE for covid-19 immunisation. The patient experienced cough, short of breath, keeps clearing throat on 10Nov2021, and left arm really hurts, heart rate is 116 currently and booster on an unspecified date. Caller (patient) reported that, her Pfizer COVID-19 vaccine booster dose yesterday on 09Nov20211, around 14:30 she is complaining of a deep cough and having to clear her throat and while on the phone looked at her watch and her resting heart rate is 116 currently and since she is coughing so much right now is starting to get short of breath. She is wondering if this could be a possible side effect of the booster. She said she is just wondering, because she hasn't read it anywhere, if these are possible side effects. Patient denies any other medications, medical conditions, labs, testing, or treatments relevant to events. Patient stated that she does take medications, she doesn't think they are relevant because she took them before. Caller states that these symptoms started today. The patient underwent lab tests and procedures which included heart rate increased: 116 on an unspecified date. No therapeutic measures were taken as a result of the events. The outcome of the events was reported as unknown.  Follow-up attempts are completed. No further information is expected.
red rash (over the face, neck, chest, and the backside (halfway down the waist); Fever (99.9F); Sore Arm; Tredness; This case was reported by a consumer via call center representative and described the occurrence of red rash in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Zostavax with an associated reaction of herpes zoster (received years ago and then developed shingles).   On 3rd June 2021, the patient received the 1st dose of Shingrix (intramuscular) 50 ug. In June 2021, less than a week after receiving Shingrix, the patient experienced red rash, fever, pain in arm and tiredness. In June 2021, the outcome of the red rash, fever, pain in arm and tiredness were recovered/resolved.   It was unknown if the reporter considered the red rash, fever, pain in arm and tiredness to be related to Shingrix.  Additional details were reported follows: The patient reported this case for herself. The reporter mentioned that she received Zostavax years ago and then developed shingles. Later, she was advised to take Shingrix by her health care professional. The patient received shingrix in the left deltoid. The patient experienced tiredness, sore arm, fever 99.9 degree F , red rash all over the face, neck, chest, and the backside, halfway down the waist. The side effects were resolved on the 4th day post vaccination. The reporter did not consent to follow-up.
Hardness; Itching; Swelling; Redness; Rash; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE INDURATION (Hardness), VACCINATION SITE PRURITUS (Itching), VACCINATION SITE SWELLING (Swelling), VACCINATION SITE ERYTHEMA (Redness) and VACCINATION SITE RASH (Rash) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Jan-2021, the patient experienced VACCINATION SITE INDURATION (Hardness), VACCINATION SITE PRURITUS (Itching), VACCINATION SITE SWELLING (Swelling), VACCINATION SITE ERYTHEMA (Redness) and VACCINATION SITE RASH (Rash). At the time of the report, VACCINATION SITE INDURATION (Hardness), VACCINATION SITE PRURITUS (Itching), VACCINATION SITE SWELLING (Swelling), VACCINATION SITE ERYTHEMA (Redness) and VACCINATION SITE RASH (Rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant mdications were reported.  No treatment information was provided.    Reporter did not allow further contact; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Body shook, eyes rolled back and went limp. No cyanosis. This lasted for 30 seconds. Dx'd with seizure and admitted to the hospital; afebrile at the time. Pt was pale and groggy after the event.
I had a miscarriage (spontaneous abortion) on March 14, 2021. I was 12 weeks pregnant at the time of miscarriage.
hard knot; This case was reported by a consumer via interactive digital media and described the occurrence of induration in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced induration. On an unknown date, the outcome of the induration was unknown.   It was unknown if the reporter considered the induration to be related to Shingrix.  Additional details were reported as follows: The case was reported by the patient. The age at vaccination was not reported. The reporter asked how long should a hard knot last after the Vaccine. No contact details were available.
Hospital Course:  80 yo M with h/o CAD, HTN, Hypothryoidism, BPH with mild COVID-19 x 4 days pta who was admitted with acute appendicitis, complicated by Bacteroides bacteremia. Patient underwent a laparoscopic appendectomy for acute appendicitis. He tolerated his procedure well. He was treated initially with zosyn. On POD2 he was transitioned from zosyn to metronidazole and is to complete a total 14 day course of antibiotics. He should follow up with his surgeon on 4/20 and his primary care physician.    Issues Requiring Follow Up:  - Completion of antibiotics; Flagyl for a total of 14 days - Follow up with primary care physician - Follow up with surgeon 4/20  - Hydronephrosis incidentally seen on imagining, follow up outpt
she had a reaction to something; swelling on her face; swollen glands near her ear and on her neck; rash that was red at top of her face near the ear; This spontaneous case was reported by a consumer and describes the occurrence of ADVERSE EVENT (she had a reaction to something), SWELLING FACE (swelling on her face), RASH ERYTHEMATOUS (rash that was red at top of her face near the ear) and LYMPHADENOPATHY (swollen glands near her ear and on her neck) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination.     Concomitant products included METFORMIN, OLMESARTAN MEDOXOMIL, ROSUVASTATIN, DILTIAZEM, SITAGLIPTIN and VITAMIN D3 for an unknown indication.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form(s). On 12-Feb-2021, the patient experienced RASH ERYTHEMATOUS (rash that was red at top of her face near the ear). On 14-Feb-2021, the patient experienced LYMPHADENOPATHY (swollen glands near her ear and on her neck). On an unknown date, the patient experienced ADVERSE EVENT (she had a reaction to something) and SWELLING FACE (swelling on her face). At the time of the report, ADVERSE EVENT (she had a reaction to something), RASH ERYTHEMATOUS (rash that was red at top of her face near the ear) and LYMPHADENOPATHY (swollen glands near her ear and on her neck) had not resolved and SWELLING FACE (swelling on her face) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment information included an unknown dosage of steroids.    This case was linked to MOD21-081896 (E2B Linked Report). This case was linked to MOD21-030460 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 26-Apr-2021: No specific follow-up information recorded.   This case was linked to MOD21-081896 (E2B Linked Report). This case was linked to MOD21-030460 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 12-May-2021: concomitant medications , new event information were adedd; Sender's Comments:  MOD21-081896:2nd Dose
Approx. 6-8 hours after vaccine administration, began to complain of "boo-boo" (pain), mild erythema and edema of thigh. Child complaint of "hurts" when walking. Right thigh received DTAP and left rectus femaris.
Patient received 1st dose of Pfizer COVID vaccine on 4/1/21. The next day, she developed fever, was told that she had a sinus infection, and was treated with amoxicillin. Patient tested positive for COVID on 4/7/21 at her primary care doctor's office. On 4/8/21, patient presented to the ER with cough, shortness of breath, fever, chills, and weakness, but was sent home. Patient returned to the ER on 4/9/21 with worsening symptoms and was admitted to the hospital for COVID treatment.
Patient received pediatric dose (orange cap) of covid-19 Pfizer vaccine instead of the adult (purple cap) dose. The pediatric vaccine was also not diluted prior to administration. In addition 0.25mL was given instead of 0.3 mL. The patient had no adverse reaction or symptoms due to the dosing error.
Systemic: Fainting / Unresponsive-Mild, Additional Details: Patient fainted as soon as the needle come out of her body and the fainting lasted for less than a minute
Severe multifactoral health issues as described in previous question. Treatment is still current and ongoing. Adverse reaction that it could be posssiblity of health issues coming from Shingles vaccine wasnt noticed until December 2016.
Dizziness, uncontrolled muscle movement, passed out, nauseous, clammy, weak muscles.
Scheduled for the second Pfizer Covid vaccine on 25March2021, caller canceled the appointment due to traveling; Body aches; Fever; Chills; This is a spontaneous report from a contactable consumer (patient). A male patient of an unspecified age received first dose bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported), dose 1 via an unspecified route of administration on 04Mar2021 as 1st dose, single for COVID-19 immunization. Medical history and concomitant medications were not reported. On 05Mar2021 the patient experienced body aches, fever, chills. scheduled for the second pfizer covid vaccine on 25march2021, patient canceled the appointment due to traveling. The following morning caller experienced body aches, fever & chills. Caller voiced that he previous spoke with someone about the symptoms, he needed to know about scheduling. Per caller he noticed in New York Times that if you have tested positive for Covid in the past you only need one vaccine. Asking if he only needs the one Pfizer Covid vaccine or both. The caller got the first dose last 04Mar and second dose was on 25Mar, however he wants to move his second dose to later date because he needs to be somewhere, more so he tested positive last year April of Covid and after his first shot he experienced the same symptoms of Covid like fever chills and body ache for 24 hours .The patient underwent lab tests and procedures which included sars-cov-2 antibody test: positive on he tested positive last year Apr of Covid. The outcome of the events was unknown.  No follow-up attempts are needed. No further information is expected.
weird feeling, itchy all over mostly arms.  increased phelgm with throat / tongue/ swelling;  anxious.
'In various stages of healing papules with crust, vesicles on face." (per ED note 6/9/07)
Full body hives; mild symptoms; This spontaneous case was reported by a physician and describes the occurrence of ADVERSE EVENT (mild symptoms) and URTICARIA (Full body hives) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Jan-2021, the patient experienced ADVERSE EVENT (mild symptoms). On 02-Feb-2021, the patient experienced URTICARIA (Full body hives). At the time of the report, ADVERSE EVENT (mild symptoms) and URTICARIA (Full body hives) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   Treatment included - She has been self-medicating with Benadryl and perhaps getting better but she is not sure.
felt tired; Irregular Heart Beat; This is a spontaneous report from a contactable consumer (the patient). A 79-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot Number: EN6208), dose 1 via an unspecified route of administration, administered in Arm Left on 10Mar2021 14:00 (at the age of 79-years-old) as a single dose for COVID-19 immunisation at Doctor's office/urgent care. Medical history included triple bypass in 2018 and enlarged prostate from an unknown date, COVID-19 from an unknown date (prior to vaccination). Concomitant medications included tamsulosin taken for an unspecified indication, start and stop date were not reported; atorvastatin taken for an unspecified indication, start and stop date were not reported; ezetimibe taken for an unspecified indication, start and stop date were not reported. The patient has no known allergies. The patient did not receive any other vaccine in four weeks. The patient was not tested for COVID post vaccination. On 10Mar2021, the patient experienced irregular heart beat. On 11Mar2021, he felt tired. It was reported that "Irregular Heart Beat on the day of the shot and the following day. Also felt tired the day following." The patient underwent lab tests and procedures which included heart beat: irregular on 10Mar2021 and heart beat: irregular on 11Mar2021. The patient did not receive any treatment for adverse events. The outcome of events was recovered on unspecified date in Mar2021.  No follow-up attempts are possible. No further information is expected.